MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Biotech / Vital Therapies delays IPO on ‘poor market conditions’

Vital Therapies delays IPO on ‘poor market conditions’

November 22, 2013 By Arezu Sarvestani Leave a Comment

Vital Therapies delays IPO on 'poor market conditions'

San Diego, Calif.-based Vital Therapies Inc. decided to put off its initial public offering for an undisclosed period of time, hoping market conditions will improve for its liver failure cell-based therapy.

The IPO was supposed to launch this week, according to Renaissance Capital IPO Center, which cited "poor market conditions" as the reason for the delay.

The company earlier this month laid out its final pricing for the IPO at $16 to $18 per share for 4.4 million shares, a total take of up to $79.2 million.

Vital Therapies, which was founded about 10 years ago, hopes its ELAD artificial liver may help stabilize liver function in treatment of patients with acute organ failure, hepatitis B and alcohol hepatitis. Vital Therapies earlier this year drummed up $22.5 million in an equity funding round and launched a phase III trial comparing ELAD treatment to the standard-of-care in patients with alcohol-induced liver deterioration.

ELAD is a system of lumen catheters, plasma circuits, and fluid recirculation components that functionally overrides a failing liver to detoxify blood and create proteins.

The healthcare products maker plans to use the funds for developing and chasing approval for the ELAD system and to "facilitate our future access to the public equity markets," according to the registration statements. Funds raised from this IPO should get the company at least through the next year, at should be sufficient to fund operations through the point at which Vital Therapies expects to get initial data on its Phase III program, according to company statements.

Filed Under: Biotech, Initial Public Offering (IPO), News Well, Wall Street Beat Tagged With: Vital Therapies

In case you missed it

  • Edwards projects $5 billion in sales for 2020
  • SPR Therapeutics announces 1000th placement of nerve stimulation device
  • The best places to work for medtech sales reps
  • DePuy Synthes issues urgent field safety notice for USS II Polyaxial 3D heads
  • Haemonetics (HAE) launches SafeTrace Tx in North America
  • Vicarious Surgical wins FDA breakthrough designation for surgical robot
  • Natus Medical issues field safety notice for snap electrode leads
  • J&J’s Ethicon gets to substitute 20 new claims on surgical stapler patent
  • Minerva Surgical raises $10m
  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • Orthofix names new president of global spine business
  • J&J Vision launches Tecnis Toric II intraocular lens in U.S.
  • NOUS Imaging picks up $6.6m for brain-imaging software
  • MicroVention issues safety notice for Azur endovascular embolization products
  • New study touts positive long-term results for Boston Sci’s Watchman
  • 3M issues safety notice for Durapore Advanced surgical tape
  • FDA clearance positions Sight Diagnostics to deliver on two-drop blood testing promise

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS